JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target
JP Morgan analyst Jessica Fye reinstates Amarin Corp (NASDAQ:AMRN) with a Underweight and announces $13 price target.
Read original at benzingaStocks · News reference
Amarin Highlights Recent FDA Approval Of Injectable Apolipoprotein C-III Therapies For Treatment Of Severe Hypertriglyceridemia, Defined As Triglycerides Greater Than Or Equal To 500 mg/dL
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 30, 2026, 8:18 PM
- Checked
- Jun 30, 2026, 8:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — AMARIN CORP PLC\UK (AMRN)
Filed: 2026-07-29 AccNo: 0001193125-26-323841 Size: 777 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Read original at edgarAmarin Corp Q2 Sales $42.211M Miss $44.550M Estimate
Read original at benzinga